Epidermal growth factor receptor (EGFR) intron 1 polymorphism and clinical outcome in pancreatic adenocarcinoma

Andrey Frolov; J. Spencer Liles; Andrew V. Kossenkov; Ching Wei D. Tzeng; Nirag Jhala; Peter Kulesza; Shyam Varadarajulu; Mohamad Eloubeidi; Martin J. Heslin; J. Pablo Arnoletti

doi:10.1016/j.amjsurg.2009.10.014

Epidermal growth factor receptor (EGFR) intron 1 polymorphism and clinical outcome in pancreatic adenocarcinoma

Andrey Frolov, J. Spencer Liles, Andrew V. Kossenkov, Ching Wei D. Tzeng, Nirag Jhala, Peter Kulesza, Shyam Varadarajulu, Mohamad Eloubeidi, Martin J. Heslin, J. Pablo Arnoletti

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Background: Epidermal growth factor receptor (EGFR) intron 1 has a polymorphic region of CA repeats that is believed to be associated with increased EGFR expression, tumor aggressiveness, and worse survival in cancer patients. Methods: A large population of pancreatic adenocarcinoma patients was investigated to evaluate this polymorphism as a potential prognostic marker of clinical outcome. Deoxyribonucleic acid obtained from 50 resected pancreatic adenocarcinomas and from 85 diagnostic endoscopic ultrasound-guided fine-needle aspiration procedures corresponding to patients with unresectable tumors was included. The correlation between CA repeat length and EGFR messenger ribonucleic acid levels was also examined. Results: Analysis of the 135 patients revealed no correlation between EGFR intron 1 CA repeat length and tumor stage. There was no difference in overall patient survival when stratified by allele length. A correlation between EGFR intron 1 length and EGFR transcript and protein levels could not be established. Conclusions: The length of the EGFR intron 1 CA repeats does not correlate with levels of EGFR expression and cannot be used as marker of clinical prognosis in pancreatic cancer patients.

Original language	English (US)
Pages (from-to)	398-405
Number of pages	8
Journal	American Journal of Surgery
Volume	200
Issue number	3
DOIs	https://doi.org/10.1016/j.amjsurg.2009.10.014
State	Published - Sep 2010
Externally published	Yes

Keywords

EGFR
Intron 1 polymorphism
Pancreatic cancer

ASJC Scopus subject areas

Surgery

Access to Document

10.1016/j.amjsurg.2009.10.014

Cite this

@article{09642b50c7504edcb0691f9ac8d2ece8,

title = "Epidermal growth factor receptor (EGFR) intron 1 polymorphism and clinical outcome in pancreatic adenocarcinoma",

abstract = "Background: Epidermal growth factor receptor (EGFR) intron 1 has a polymorphic region of CA repeats that is believed to be associated with increased EGFR expression, tumor aggressiveness, and worse survival in cancer patients. Methods: A large population of pancreatic adenocarcinoma patients was investigated to evaluate this polymorphism as a potential prognostic marker of clinical outcome. Deoxyribonucleic acid obtained from 50 resected pancreatic adenocarcinomas and from 85 diagnostic endoscopic ultrasound-guided fine-needle aspiration procedures corresponding to patients with unresectable tumors was included. The correlation between CA repeat length and EGFR messenger ribonucleic acid levels was also examined. Results: Analysis of the 135 patients revealed no correlation between EGFR intron 1 CA repeat length and tumor stage. There was no difference in overall patient survival when stratified by allele length. A correlation between EGFR intron 1 length and EGFR transcript and protein levels could not be established. Conclusions: The length of the EGFR intron 1 CA repeats does not correlate with levels of EGFR expression and cannot be used as marker of clinical prognosis in pancreatic cancer patients.",

keywords = "EGFR, Intron 1 polymorphism, Pancreatic cancer",

author = "Andrey Frolov and Liles, {J. Spencer} and Kossenkov, {Andrew V.} and Tzeng, {Ching Wei D.} and Nirag Jhala and Peter Kulesza and Shyam Varadarajulu and Mohamad Eloubeidi and Heslin, {Martin J.} and Arnoletti, {J. Pablo}",

year = "2010",

month = sep,

doi = "10.1016/j.amjsurg.2009.10.014",

language = "English (US)",

volume = "200",

pages = "398--405",

journal = "American Journal of Surgery",

issn = "0002-9610",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Epidermal growth factor receptor (EGFR) intron 1 polymorphism and clinical outcome in pancreatic adenocarcinoma

AU - Frolov, Andrey

AU - Liles, J. Spencer

AU - Kossenkov, Andrew V.

AU - Tzeng, Ching Wei D.

AU - Jhala, Nirag

AU - Kulesza, Peter

AU - Varadarajulu, Shyam

AU - Eloubeidi, Mohamad

AU - Heslin, Martin J.

AU - Arnoletti, J. Pablo

PY - 2010/9

Y1 - 2010/9

N2 - Background: Epidermal growth factor receptor (EGFR) intron 1 has a polymorphic region of CA repeats that is believed to be associated with increased EGFR expression, tumor aggressiveness, and worse survival in cancer patients. Methods: A large population of pancreatic adenocarcinoma patients was investigated to evaluate this polymorphism as a potential prognostic marker of clinical outcome. Deoxyribonucleic acid obtained from 50 resected pancreatic adenocarcinomas and from 85 diagnostic endoscopic ultrasound-guided fine-needle aspiration procedures corresponding to patients with unresectable tumors was included. The correlation between CA repeat length and EGFR messenger ribonucleic acid levels was also examined. Results: Analysis of the 135 patients revealed no correlation between EGFR intron 1 CA repeat length and tumor stage. There was no difference in overall patient survival when stratified by allele length. A correlation between EGFR intron 1 length and EGFR transcript and protein levels could not be established. Conclusions: The length of the EGFR intron 1 CA repeats does not correlate with levels of EGFR expression and cannot be used as marker of clinical prognosis in pancreatic cancer patients.

AB - Background: Epidermal growth factor receptor (EGFR) intron 1 has a polymorphic region of CA repeats that is believed to be associated with increased EGFR expression, tumor aggressiveness, and worse survival in cancer patients. Methods: A large population of pancreatic adenocarcinoma patients was investigated to evaluate this polymorphism as a potential prognostic marker of clinical outcome. Deoxyribonucleic acid obtained from 50 resected pancreatic adenocarcinomas and from 85 diagnostic endoscopic ultrasound-guided fine-needle aspiration procedures corresponding to patients with unresectable tumors was included. The correlation between CA repeat length and EGFR messenger ribonucleic acid levels was also examined. Results: Analysis of the 135 patients revealed no correlation between EGFR intron 1 CA repeat length and tumor stage. There was no difference in overall patient survival when stratified by allele length. A correlation between EGFR intron 1 length and EGFR transcript and protein levels could not be established. Conclusions: The length of the EGFR intron 1 CA repeats does not correlate with levels of EGFR expression and cannot be used as marker of clinical prognosis in pancreatic cancer patients.

KW - EGFR

KW - Intron 1 polymorphism

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=77956189333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956189333&partnerID=8YFLogxK

U2 - 10.1016/j.amjsurg.2009.10.014

DO - 10.1016/j.amjsurg.2009.10.014

M3 - Article

C2 - 20409526

AN - SCOPUS:77956189333

SN - 0002-9610

VL - 200

SP - 398

EP - 405

JO - American Journal of Surgery

JF - American Journal of Surgery

IS - 3

ER -

Epidermal growth factor receptor (EGFR) intron 1 polymorphism and clinical outcome in pancreatic adenocarcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this